Management of anlotinib‐related adverse events in patients with advanced non‐small cell lung cancer: Experiences in ALTER‐0303-Reference-Cited by-同舟云学术

Management of anlotinib‐related adverse events in patients with advanced non‐small cell lung cancer: Experiences in ALTER‐0303

Published:2019-01-21 Issue:3 Volume:10 Page:551-556
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Si Xiaoyan¹^ORCID,Zhang Li¹,Wang Hanping¹,Zhang Xiaotong¹,Wang Mengzhao¹,Han Baohui²,Li Kai³,Wang Qiming⁴,Shi Jianhua⁵,Wang Zhehai⁶,Cheng Ying⁷,Shi Yuankai⁸^ORCID,Chen Weiqiang⁹,Wang Xiuwen¹⁰,Luo Yi¹¹,Nan Kejun¹²,Jin Faguang¹³

Affiliation:

1. Respiratory MedicinePeking Union Medical College Hospital Beijing China

2. Department of PulmonaryShanghai Chest Hospital Shanghai China

3. Department of Thoracic OncologyTianjin Medical University Cancer Hospital Tianjin China

4. Department of Internal MedicineHenan Province Tumor Hospital Zhengzhou China

5. Department of OncologyLinyi City Tumor Hospital Linyi China

6. Department of Internal Medicine‐OncologyShandong Province Tumor Hospital Jinan China

7. Department of Thoracic OncologyJilin Province Tumor Hospital Changchun China

8. Department of Medical OncologyChinese Academy of Medical Sciences Cancer Hospital Beijing China

9. Department of Pulmonary MedicineLanzhou Military General Hospital Lanzhou China

10. Department of ChemotherapyQilu Hospital, Shandong University Jinan China

11. Department of Medical OncologyHunan Province Tumor Hospital Changsha China

12. Department of OncologyFirst Affiliated Hospital of Xi'an Jiaotong University Xi'an China

13. Department of Respiratory DiseasesTangdu Hospital Xi'an China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.12977

Reference16 articles.

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

2. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

3. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

4. Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor

5. Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of anlotinib as maintenance therapy in patients with advanced non-small cell lung cancer achieving SD post first-line chemotherapy combined with immunotherapy;Journal of Chemotherapy;2024-09

2. Extracellular vesicle miRNAs for predicting the efficacy of late-line treatment with anlotinib in patients with lung adenocarcinoma;Cancer Nanotechnology;2024-07-02

3. Combination of anlotinib and second-line chemotherapy as surrogate to reduce immunosuppression in patients with advanced non-small cell lung cancer;Pakistan Journal of Medical Sciences;2024-06-15

4. Efficacy and safety of EGFR-TKIs for non-small cell lung cancer: A meta-analysis of randomized controlled clinical trials;Medicine;2024-06-07

5. Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial;Lung Cancer;2024-05